Title

Prostin and Propess in Induction of Labor
Induction of Labour: A Comparison Between Propess Vaginal Delivery System and Prostin E2 Vaginal Suppositories, A Randomized Controlled Trial.
  • Phase

    Phase 3
  • Study Type

    Interventional
  • Study Participants

    200
The purpose of the study was to compare the safety and efficacy of two agents used in induction of labor Propess (Controlled release dinoprostone, PGE2, pessary) and Prostin E2 (Dinoprostone vaginal Tablet).
A controlled release hydrophilic matrix (Controlled Therapeutics Ltd., East Kilbride, Scotland) which provides a gradual release of dinoprostone (prostaglandin E2) was introduced in 1995 (Propess, Ferring Pharmaceuticals). This preparation is used for the initiation or enhancement of cervical ripening in women at or after term with a singleton pregnancy and a cephalic presentation. Prostaglandin E2 causes softening and dilatation of the cervix and subsequently produces uterine contractions which may induce labour.
Study Started
Dec 31
2010
Primary Completion
Nov 30
2011
Study Completion
Dec 31
2011
Results Posted
Oct 04
2012
Estimate
Last Update
Feb 06
2014
Estimate

Drug Propess

The vaginal insert is removed 24 h after the application. It is only to be removed earlier in case of the onset of active labour, the rupture of the membranes, or at the occurrence of hyperstimulation.

  • Other names: Intravaginal PGE2 insert

Drug Prostin E2

3 mg tab is placed in the posterior vaginal fornix. dose can be repeated every 6 hours till onset of active labour, the rupture of the membranes, or the occurrence of hyper-stimulation.

  • Other names: Dinoprostone (PGE2)vaginal tablets.

Propess Active Comparator

Propess insert is a preparation of PGE2 packaged in a hydrogel polymer matrix and designed for slow intravaginal release of 10 mg dinoprostone at a rate of 0.3 mg/h.

Prostin E2 Active Comparator

PROSTIN E2 Vaginal Suppository, an oxytocic, contains dinoprostone as the naturally occurring prostaglandin E2 (PGE2)3 mg/suppository.

Criteria

Inclusion Criteria:

Gestational age 37 weeks or more
Singleton pregnancy
Cephalic presentation.

Exclusion Criteria:

Previous cesarean section
Any contraindication for vaginal delivery
Suspected Cephalo-Pelvic Disproportion
Unexplained antepartum Hemorrhage

Summary

Propess

Prostin E2

All Events

Event Type Organ System Event Term Propess Prostin E2

Induction to Delivery Interval

Propess

22.3
hours (Mean)
Standard Deviation: 5.7

Prostin E2

21.2
hours (Mean)
Standard Deviation: 5.3

Induction to Onset of Labor Interval

Propess

18.8
hours (Mean)
Standard Deviation: 5.3

Prostin E2

17.7
hours (Mean)
Standard Deviation: 5.4

Uterine Hyper-stimulation Rate

Propess

1.0
participants

Prostin E2

1.0
participants

Need for Syntocinon Augmentation

Propess

5.0
participants

Prostin E2

10.0
participants

Normal Vaginal Delivery Rate

Propess

79.0
participants

Prostin E2

85.0
participants

Total

200
Participants

Age, Continuous

26.4
years (Mean)
Standard Deviation: 4.7

Body mass index

23.3
kg/m^2 (Mean)
Standard Deviation: 3.1

Gestational age

40.5
weeks (Mean)
Standard Deviation: 1.2

Parity

Sex: Female, Male

Overall Study

Propess

Prostin E2